Disclosures for "Assessing Risk for Poor Neurodevelopmental Outcomes in Pediatric Mitochondrial Disease"
-
Dr. Alkhyeli has nothing to disclose.
-
Dr. Owen has nothing to disclose.
-
Miss Struver has nothing to disclose.
-
Dr. Haas has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for SPARC. Dr. Haas has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB Pharma. Dr. Haas has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for Various Law Firms. Dr. Haas has stock in Various Companies Stock Trading. The institution of Dr. Haas has received research support from NIH North American Mitochondrial Disease Consortium. The institution of Dr. Haas has received research support from Reneo Pharma. The institution of Dr. Haas has received research support from Astellas Pharma. The institution of Dr. Haas has received research support from Acadia Pharma. The institution of Dr. Haas has received research support from Taysha Gene Therapies. The institution of Dr. Haas has received research support from Tisento Pharma.
-
Dr. Yang has received research support from Pediatric Epilepsy Research Foundation. Dr. Yang has received research support from NIH.